clinical trial webpage (BeiGene Inc)
90
Structured Review
BeiGene Inc
clinical trial webpage
Clinical Trial Webpage, supplied by BeiGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clinical+trial+webpage/clinical+trial+webpage/pm40411966-178-14-8
Average 90 stars, based on 1 article reviews
Clinical Trial Webpage, supplied by BeiGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clinical+trial+webpage/clinical+trial+webpage/pm40411966-178-14-8
Average 90 stars, based on 1 article reviews
clinical trial webpage - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: ACQUIRED MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY CLL WHO PROGRESSED IN THE ALPINE STUDY. Article Snippet: Qualified researchers may submit Article Title: AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer. Article Snippet: H I G H L I G H T S • A critical unmet need for new treatment options remains in patients with recurrent or metastatic (R/M) cervical cancer (CC).. • AdvanTIG-202 evaluated the efficacy/safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD1) mAbs in R/M CC.. • In R/M CC with prior chemotherapy, ociperlimab + tislelizumab had promising efficacy in both all-comers and PD-L1+ subgroup. Article Title: Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL. Article Snippet: Qualified researchers may submit Article Title: Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis. Article Snippet: Qualified researchers may submit Article Title: Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies Article Snippet: Qualified researchers may submit Article Title: ACQUIRED MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY CLL WHO PROGRESSED IN THE ALPINE STUDY. Article Snippet: Qualified researchers may submit Article Title: Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies. Article Snippet: Qualified researchers may submit Article Title: Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study Article Snippet: Qualified researchers may submit data requests or research proposals for |